Protocol Ledger

NCT04511819 · Phase III · TERMINATED

Losmapimod Safety and Efficacy in COVID-19

Interventional Phase III clinical trial protocol NCT04511819 sponsored by Fulcrum Therapeutics in Infectious Disease and Vaccines, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2020-08-28 Enrollment: 52 participants (ACTUAL) Federal Source: clinicaltrials.gov/study/NCT04511819
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)52 participants (ACTUAL)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT04511819
Protocol FieldVerified Registry Value
NCT IdentifierNCT04511819
Consolidated Lead SponsorFulcrum Therapeutics
Therapeutic Condition CohortInfectious Disease and Vaccines
Clinical Trial PhasePhase III
Overall Recruitment StatusTERMINATED
Registered Enrollment52 participants (ACTUAL)
Registered Start Date2020-08-28
WhyStopped ClassificationFunding / COVID / Operational

Named U.S. Hospital Clinical Research Sites

Search related sites and sponsors in the Interactive Directory, explore Infectious Disease and Vaccines Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI